India, Developing Nations To Press Third-World Disease Drugs At WHO Meeting (India)
This article was originally published in PharmAsia News
India and other developing nations plan to make a strong case in an April international lobbying effort for funding drugs aimed at some of the diseases plaguing their segment of the world. Diseases in the developing world, such as tuberculosis and malaria, comprise less than 10 percent of research dollars spent on drug research even though those diseases account for more than 90 percent of the diseases afflicting the world's population. The World Health Organization's decision-making body has scheduled international negotiations in Switzerland in April to hear from participating nations on the issue. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?